15 reports of this reaction
3.9% of all ACETAMINOPHEN 325MG reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for ACETAMINOPHEN 325MG, manufactured by Allegiant Health. There are 15 FDA adverse event reports linking ACETAMINOPHEN 325MG to HEADACHE. This represents approximately 3.9% of all 383 adverse event reports for this drug.
Patients taking ACETAMINOPHEN 325MG who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among ACETAMINOPHEN 325MG users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for ACETAMINOPHEN 325MG:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 15 FDA reports for ACETAMINOPHEN 325MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 3.9% of all adverse event reports for ACETAMINOPHEN 325MG, making it one of the most commonly reported side effect.
If you experience headache while taking ACETAMINOPHEN 325MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.